Overview
Crystalys Therapeutics is a biopharmaceutical company developing dotinurad for gout, with the program moving through global Phase 3 development and preparation for commercialization. Its target market is gout treatment, where the company is focused on bringing the therapy to patients and prescribing clinicians internationally. The company announced a $130 million Series B financing on July 22, 2026, bringing disclosed funding to $130 million across one round. The round is intended to advance late-stage clinical development and commercialization activities; no AI platform or AI-enabled technology was described in the provided funding context.
Funding History
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
Frequently Asked Questions
- How much funding does AI Funding track for Crystalys Therapeutics?
- AI Funding tracks $130M for Crystalys Therapeutics across 1 funding round in this database.
- What does Crystalys Therapeutics do?
- Crystalys Therapeutics is a biopharmaceutical company developing dotinurad for gout, with the program moving through global Phase 3 development and preparation for commercialization. Its target market is gout treatment, where the company is focused on bringing the therapy to patients and prescribing clinicians internationally. The company announced a $130 million Series B financing on July 22, 2026, bringing disclosed funding to $130 million across one round. The round is intended to advance late-stage clinical development and commercialization activities; no AI platform or AI-enabled technology was described in the provided funding context.
- Where is Crystalys Therapeutics headquartered?
- Crystalys Therapeutics is headquartered in San Francisco, CA.
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.